Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NRBO NeuroBo Pharmaceuticals

Watchlist
1.730
+0.350+25.36%
Close  12/08 16:00 ET
1.870
+0.140+8.09%
Post Mkt Price 12/08 19:59 ET
High
1.890
Open
1.380
Turnover
13.12M
Low
1.370
Pre Close
1.380
Volume
7.75M
Market Cap
11.25M
P/E(TTM)
Loss
52wk High
63.850
Shares
6.50M
P/E(Static)
Loss
52wk Low
1.130
Float Cap
10.95M
Bid/Ask %
-85.71%
Historical High
16192.494
Shs Float
6.33M
Volume Ratio
6.63
Historical Low
1.130
Dividend TTM
--
Div Yield TTM
--
P/B
1.89
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
122.46%
Amplitude
37.68%
Avg Price
1.693
Lot Size
1
Float Cap
10.95M
Bid/Ask %
-85.71%
Historical High
16192.494
Shs Float
6.33M
Volume Ratio
6.63
Historical Low
1.130
Dividend TTM
--
P/B
1.89
Dividend LFY
--
Turnover Ratio
122.46%
Amplitude
37.68%
Avg Price
1.693
Lot Size
1
Price Forecast

News

Comment

Sign in to post a comment

No comment yet

Company Overview More
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
CEO: Dr. Ben Gil Price
Market: NASDAQ
Listing Date: 08/05/2016
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist